DOI: 10.1055/s-00000134

Diabetologie und Stoffwechsel

LinksClose Window

References

Eli Lilly and Company.
Trulicity(R) (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes 2018.
Available from:
https://investor.lilly.com/news-releases/news-release-details/trulicityr-dulaglutide-demonstrates-superiority-reduction

Download Bibliographical Data

We do not assume any responsibility for the contents of the web pages of other providers.